A Phase Ib Dose Escalation Study of Afatinib in Combination With Cetuximab in Patients With Advanced Solid Tumours

Trial Profile

A Phase Ib Dose Escalation Study of Afatinib in Combination With Cetuximab in Patients With Advanced Solid Tumours

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Jun 2017

At a glance

  • Drugs Afatinib (Primary) ; Cetuximab
  • Indications Carcinoma; Head and neck cancer; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 02 Dec 2016 Results assessing safety and efficacy of afatinib plus standard-dose cetuximab in patients with advanced solid tumours presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
    • 11 May 2016 Status changed from active, no longer recruiting to completed.
    • 16 Dec 2015 Planned End Date changed from 1 Nov 2015 to 1 May 2016 as reported by the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top